Performance of [18F]Flutemetamol Amyloid Imaging Against the Neuritic Plaque Component of Cerad and the Current (2012) NIA-AA Recommendations for the Neuropathologic Diagnosis of Alzheimer's Disease
Introduction Performance of the amyloid tracer [18F]flutemetamol was evaluated against three pathology standard of truth (SoT) measures including neuritic plaques (CERAD â€œoriginalâ€ and â€œmodifiedâ€ and the amyloid component of the 2012 NIA-AA guidelines). Methods After [18F]flutemetamol imaging, 106 end-of-life patients who died underwent postmortem brain examination for amyloid plaque load. Blinded positron emission tomography scan interpretations by five independent electronically trained readers were compared with pathology measures. Results By SoT, sensitivity and specificity of majority image interpretations were, respectively, 91.9% and 87.5% with â€œoriginal CERAD,â€ 90.8% and 90.0% with â€œmodified CERAD,â€ and 85.7% and 100% with the 2012 NIA-AA criteria. Discussion The high accuracy of either CERAD criteria suggests that [18F]flutemetamol predominantly reflects neuritic amyloid plaque density. However, the use of CERAD criteria as the SoT can result in some false-positive results because of the presence of diffuse plaques, which are accounted for when the positron emission tomography read is compared with the 2012 NIA-AA criteria.
Medical Subject Headings
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Digital Object Identifier (DOI)
Salloway, Stephen; Gamez, Jose E.; Singh, Upinder; Sadowsky, Carl H.; Villena, Teresa; Sabbagh, Marwan N.; Beach, Thomas G.; Duara, Ranjan; Fleisher, Adam S.; Frey, Kirk A.; Walker, Zuzana; Hunjan, Arvinder; Escovar, Yavir M.; Agronin, Marc E.; Ross, Joel; Bozoki, Andrea; Akinola, Mary; Shi, Jiong; Vandenberghe, Rik; and al., et, "Performance of [18F]Flutemetamol Amyloid Imaging Against the Neuritic Plaque Component of Cerad and the Current (2012) NIA-AA Recommendations for the Neuropathologic Diagnosis of Alzheimer's Disease" (2017). Neurology. 184.